These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3157886)

  • 1. Brain amino compounds in a Huntington's disease patient on isoniazid therapy.
    Perry TL; Wall RA; Hansen S
    Neurology; 1985 May; 35(5):755-8. PubMed ID: 3157886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects.
    Urquhart N; Perry TL; Hansen S; Kennedy J
    J Neurochem; 1975 May; 24(5):1071-5. PubMed ID: 124764
    [No Abstract]   [Full Text] [Related]  

  • 3. Isoniazid therapy of Huntington disease.
    Perry TL; Wright JM; Hansen S; MacLeod PM
    Neurology; 1979 Mar; 29(3):370-5. PubMed ID: 156313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of gamma-aminobutyric acid in human brain may increase dopaminergic neuronal function.
    Perry TL; Ito M; Jones K; Hansen S
    Neurosci Lett; 1984 Sep; 50(1-3):67-71. PubMed ID: 6238245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated homocarnosine and GABA in subject on isoniazid as assessed through 1H MRS at 7T.
    Landheer K; Prinsen H; Petroff OA; Rothman DL; Juchem C
    Anal Biochem; 2020 Jun; 599():113738. PubMed ID: 32302606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain.
    Reynolds GP; Pearson SJ
    Neurosci Lett; 1987 Jul; 78(2):233-8. PubMed ID: 2442679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of brain GABA content by chronic low-dosage administration of hydrazine, a metabolite of isoniazid.
    Perry TL; Kish SJ; Hansen S; Wright JM; Wall RA; Dunn WL; Bellward GD
    J Neurochem; 1981 Jul; 37(1):32-9. PubMed ID: 7252511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. gamma-Aminobutyric acid receptors in normal human brain and Huntington disease.
    Van Ness PC; Watkins AE; Bergman MO; Tourtellotte WW; Olsen RW
    Neurology; 1982 Jan; 32(1):63-8. PubMed ID: 6275305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoniazid and Huntington's chorea.
    Perry TL
    N Engl J Med; 1978 May; 298(19):1092-3. PubMed ID: 148007
    [No Abstract]   [Full Text] [Related]  

  • 10. A double-blind clinical trial of isoniazid in Huntington disease.
    Perry TL; Wright JM; Hansen S; Thomas SM; Allan BM; Baird PA; Diewold PA
    Neurology; 1982 Apr; 32(4):354-8. PubMed ID: 6460947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia nigra gamma-aminobutyric acid receptors in Huntington's disease.
    Cross AJ; Waddington JL
    J Neurochem; 1981 Aug; 37(2):321-4. PubMed ID: 6267198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-independent, high-affinity binding of [3H]gamma-aminobutyric acid in human neurological disorders.
    Lloyd KG; Dreksler S; Shemen L; Davidson L
    Adv Exp Med Biol; 1979; 123():399-418. PubMed ID: 160192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease.
    Manyam BV; Katz L; Hare TA; Kaniefski K; Tremblay RD
    Ann Neurol; 1981 Jul; 10(1):35-7. PubMed ID: 6455963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral cation shifts and amino acids in Huntington's disease.
    Gramsbergen JB; Veenma-Van der Duin L; Venema K; Korf J
    Arch Neurol; 1986 Dec; 43(12):1276-81. PubMed ID: 2877650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.
    Bird ED; Iversen LL
    Brain; 1974 Sep; 97(3):457-72. PubMed ID: 4157009
    [No Abstract]   [Full Text] [Related]  

  • 18. Benzodiazepine receptors: the effect of GABA on their characteristics in human brain and their alteration in Huntington's disease.
    Reisine TD; Overstreet D; Gale K; Rossor M; Iversen L; Yamamura HI
    Brain Res; 1980 Oct; 199(1):79-88. PubMed ID: 6105905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease.
    Manyam BV; Ferraro TN; Hare TA
    Brain Res; 1987 Apr; 408(1-2):125-30. PubMed ID: 2885064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration.
    Tell G; Böhlen P; Schechter PJ; Koch-Weser J; Agid Y; Bonnet AM; Coquillat G; Chazot G; Fischer C
    Neurology; 1981 Feb; 31(2):207-11. PubMed ID: 6258106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.